OLIMAB PREFILLED SYRINGE contains Denosumab which belongs to the group of medicines called Monoclonal antibodies. It is used in adults to manage advanced cancer and to manage serious complications caused by bone metastasis (Ex. fractures, pressure on the spinal cord, radiation therapy, or surgery). It is also used to manage giant cell tumours of the bone, which cannot be managed by surgery, especially in adults whose bones have stopped growing. Symptoms include a visible mass and bone joints being affected (fracture, fluid buildup, limited movement, swelling, and pain in the joints).
Denosumab binds to RANKL, a protein that is essential for the formation, function, and survival of osteoclasts (the cells responsible for bone resorption). It inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength. Along with this management, your doctor might ask you to make certain lifestyle changes, such as maintaining good oral hygiene and quitting smoking. Your doctor may ask you to undergo a dental examination before you start the management. OLIMAB PREFILLED SYRINGE is not recommended for use in patients with hypocalcemia (low calcium levels in the blood) and unhealed wounds from oral surgery. Before receiving OLIMAB PREFILLED SYRINGE, inform your doctor if you have any problems with your mouth or teeth (poor dental health, gum disease, etc.).
OLIMAB PREFILLED SYRINGE is not recommended among women who are pregnant. Consult your doctor for advice before receiving OLIMAB PREFILLED SYRINGE if you are breast-feeding. OLIMAB PREFILLED SYRINGE is not recommended for children and adolescents under 18 years of age, except for adolescents with giant cell tumours of the bone whose bones have stopped growing. The most common side effects of receiving OLIMAB PREFILLED SYRINGE are pain in the bones, joints, and muscles, shortness of breath, diarrhea, hypophosphatemia (low phosphate level), and excessive sweating.
No content available
